Status:
COMPLETED
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
Lead Sponsor:
Oculus Innovative Sciences, Inc.
Conditions:
Atopic Dermatitis
Pruritus
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to find out if investigational device, RD047-26, is safe and useful for the treatment of mild to moderate atopic dermatitis.
Detailed Description
RD047-26, a device, may be tolerable and effective for the treatment of mild to moderate atopic dermatitis with associated pruritus in adults. The treatment effect will be evaluated by the subject and...
Eligibility Criteria
Inclusion
- Written informed consent
- Female or male, 18 to 65 years of age and in good general health
- Clinical diagnosis of stable mild to moderate atopic dermatitis
- Willing and able to follow study instructions and likely to complete all study requirements
Exclusion
- Severe or uncontrolled asthma
- Pregnant, nursing, or planning a pregnancy during the study; or is a WOCBP but is not willing to use an effective method of birth control
- Current enrollment in an investigational drug or device study or participation in such a study within the last 30 days prior to Baseline (Day 0)
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01232985
Start Date
October 1 2010
End Date
December 1 2010
Last Update
May 30 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology Consulting Services
High Point, North Carolina, United States, 27262